Schering-Plough's Saphris approved for schizophrenia and bipolar disorder in the US
14 August 2009
Katie McQue
The US
FDA has approved
Schering-Plough's atypical antipsychotic Saphris (asenapine maleate) sublingual tablets for the acute treatment of schizophrenia and the manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults. The approvals include its use as...
Please Login to read the full article.
14 August 2009
Katie McQue
Please Login to read the full article.
RELATED CONTENT
NEWS
- Abilify gains US approval for adjunctive maintenance use in bipolar disorder
- Mixed results for AstraZeneca in Scotland while patient access scheme swings yes for Pfizer
- Lurasidone moves forward in Canada as submission accepted
- New Japanese approvals include Xarelto for stroke prevention
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
